Physician profile
Bin Xie
NPI 1497990980
$15,091.12
in general payments reported to CMS, 2019-2025
15 companies · $411 in 2025
The $411 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,024 · 2020: $3,340 · 2021: $512 · 2022: $138 · 2023: $1,216 · 2024: $2,450 · 2025: $411.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,650 · Food and Beverage: $427.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,650.00 |
| Food and Beverage | $426.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $5,292.50 | 2019 | |
| Athenex Pharmaceutical Division, LLC | $2,521.72 | 2019-2021 | |
| Beigene USA, INC. | $1,925.00 | 2024 | Brukinsa |
| Glaxosmithkline, LLC. | $1,840.00 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,200.00 | 2023 | Gilotrif |
| Puma Biotechnology, INC. | $1,142.57 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $525.00 | 2024 | Imfinzi |
| Boston Scientific Corporation | $141.57 | 2025 | Exalt Model D |
| Sirtex Medical INC | $138.24 | 2022 | |
| Beone Medicines USA, INC. | $137.03 | 2025 | Tevimbra |
| Genentech, INC. | $132.13 | 2025 | Itovebi |
| Lilly USA, LLC | $67.21 | 2019 | |
| Celgene Corporation | $16.23 | 2023 | Reblozyl |
| Gilead Sciences, INC. | $11.92 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bin Xie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.